about
Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentPharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implicationsCardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort studyRe-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.Epidemiology of Persistent Tympanic Membrane Perforations Subsequent to Tympanostomy Tubes Assessed With Real World Data.Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorderAn algorithm to identify preterm infants in administrative claims data.Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapyEfficacy and safety of oral phenylephrine: systematic review and meta-analysis.Effects of concomitant amiodarone and haloperidol on Q-Tc interval prolongation.Medication safety infrastructure in critical-access hospitals in Florida.Patient understanding of drug risks: an evaluation of medication guide assessments.Automated medication error studies with audit supplementation were effectively designed and analyzed by time series.Oxidation-state sensitive imaging of cerium dioxide by atomic-resolution low-angle annular dark field scanning transmission electron microscopy.Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care.Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study.Sequential BART for imputation of missing covariates.Utilization of Alcohol Treatment Among HIV-Positive Women with Hazardous Drinking.Misclassification in assessment of diabetogenic risk using electronic health records.Validity and reliability of measurement instruments used in research.Anti-diabetic drug utilization of pregnant diabetic women in us managed care.Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.Rosiglitazone and the risk of adverse cardiovascular outcomes.Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.Institutional profile: University of Florida Health Personalized Medicine Program.Trends in Antiepileptic Drug Use in Children and Adolescents With Epilepsy.Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study.Clinical and Sociodemographic Factors Associated With Attention-Deficit/Hyperactivity Disorder in Patients With Cystic Fibrosis.Development of a refill pattern method to measure polypharmacy in administrative claims databases.An in-depth analysis of medication errors in hospitalized patients with HIV.Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder.Prevalence of Psychotherapy Surrounding Initiation of Psychotropic Polypharmacy in the Medicaid-Insured Population, 1999-2010.Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.Prevalence of ADHD in Publicly Insured Adults.Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries.Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
P50
Q27028197-8528A9C0-9C52-40F9-923D-7085C340DBF5Q28295134-3D04B82B-1E34-476F-AB49-9D6AA11E571CQ28729087-1679569F-B1E1-40D6-9BF6-CD0E30CEB9C4Q30660067-C9294D0F-0ABB-4847-90BA-6471753DFCAFQ31131211-3FC9116B-72EB-4B9B-81AD-F7214670B7B4Q33160890-4F378385-A080-4B38-82F1-158BC37311C7Q34232924-0845AAC5-BACA-4C86-AD44-BC22FFA9DE3CQ34367324-27A9B79D-ADC2-4C89-96A3-DB73A182C8CAQ34607745-235440A3-0DCA-45EC-ADFB-7B95250D5D7DQ34884267-3F68AB19-DA2B-4607-B84C-D47C6E956E84Q36399249-E421CA62-9D62-41BC-AC9C-EBE6E852D72DQ36522901-8FF9D038-870E-4B62-911E-EB676C1D38B4Q36559959-EDDEAD2B-7DBC-4185-B2D8-AF63E89A0526Q36592153-9DDA7374-CF28-41BA-90BD-A31973621D1AQ36838216-54C0D84F-F581-42BA-A362-18BBEFC5C54CQ36897831-1D7DBA59-7619-44C4-BB4E-FE1C2557E904Q36974278-E3587978-0820-4B66-BF61-506D4597AAE7Q37025748-737A50BC-45F7-44FA-A66B-B912E96CF89AQ37090964-852C363F-6D4A-4598-8068-DEE27EA35967Q37233836-733F4531-BB44-456F-89B7-4DA2535286B9Q37329802-8E623A0E-4D37-4939-B078-559CFC309A88Q37502324-D324D9AD-67CC-4F82-885C-C0D7D5C212ACQ37709983-F4C29DA5-D91D-4513-8A87-AC67CF85162CQ37877123-6CF30FBF-AD23-40B1-AF0A-1CAA25A27CBDQ38126419-C3C87B9C-8190-482F-97F7-D8BDB56D7AFDQ38371889-0C65A319-95F2-423F-9E4B-7D2ED6B0D27DQ38400197-A3096CC5-1B65-4E75-B1A6-9F97604873E3Q38679096-35007628-1F22-4FE2-878D-97A7123E4A31Q38886500-5198FCD5-EF62-4DF5-9E0D-DA58145FEF7EQ39049894-CF7BBC6F-898E-4C77-B338-0594C66C50D6Q39486862-2B209C10-A702-4B94-B4AA-88844614D5D7Q39761262-6FF64DAA-4CA0-44FC-B9C5-5DDBFB08E5B6Q40090778-5D53AA07-F3B0-44B5-A953-CD61E781C58AQ40138027-0EFE6898-6952-4CCE-B824-6FA43BFD277FQ40195923-5A242F82-2E37-4F04-896D-1FCE020C6E74Q40202958-7DDC0B93-BDDA-4675-B064-EB0AA8760F61Q40265061-622C5364-F2FD-4AB8-B67E-55ABAD4B0CDCQ40721258-152F4FB5-3F17-4444-8B62-73114FFB2692Q41103936-E1D3ADB4-D829-472E-94E1-791D2F1912F2Q42262424-AE4EAF7A-A558-4C42-A311-B8B4313CE90E
P50
description
Forscherin
@de
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Almut G Winterstein
@ast
Almut G Winterstein
@es
Almut G Winterstein
@nl
Almut G Winterstein
@sl
Almut G. Winterstein
@bar
Almut G. Winterstein
@de
Almut G. Winterstein
@en
Almut G. Winterstein
@fr
type
label
Almut G Winterstein
@ast
Almut G Winterstein
@es
Almut G Winterstein
@nl
Almut G Winterstein
@sl
Almut G. Winterstein
@bar
Almut G. Winterstein
@de
Almut G. Winterstein
@en
Almut G. Winterstein
@fr
prefLabel
Almut G Winterstein
@ast
Almut G Winterstein
@es
Almut G Winterstein
@nl
Almut G Winterstein
@sl
Almut G. Winterstein
@bar
Almut G. Winterstein
@de
Almut G. Winterstein
@en
Almut G. Winterstein
@fr
P1053
A-3017-2014
P106
P21
P31
P3829
P496
0000-0002-6518-5961